NYSEFinancialsInsurance - BrokersSnapshot 2026-08-31
Reading MRSH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Marsh McLennan grows revenue about 10% in 2026. Adjusted EPS rises 8% to $3.29. The company has stable profit margins and a strong market position. Free cash flow yield is solid at 6%.
Revenue growth could slow below 6% if demand weakens. Profit margins may compress due to cost pressures. Debt from new credit agreements could limit financial flexibility.
The market prices in about 5.5% revenue growth and values the stock roughly 15% above our fair value near $155. Our fair value is below the Street median, reflecting cautious optimism on growth and margins.
Breaks if: adjusted EPS growth falls below 5% in FY26
Breaks if: Leverage or liquidity deteriorates materially beyond historical norms
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on maintaining strong financial performance. The current thesis state is intact, supported by recent earnings growth and a favorable sector backdrop.
The valuation is considered expensive compared to peers, reflecting a durable premium. The market seems to have priced in a level of fragility due to weak execution quality, but not to an extreme extent.
Fundamentals are likely to remain strong, as management has consistently prioritized earnings growth and capital allocation. However, there is a moderate risk of missing expectations, especially given recent industry trends.
The thesis hinges on the performance of sector bellwethers like AON, AJG, and WTW. If these companies continue to perform well, MRSH could benefit from sustained momentum, but any negative shifts could pose risks.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No progress or setbacks in Thrive program efficiency gains by FY26
Breaks if: YoY revenue growth falls below 6% in FY26
Overall, MRSH's performance and management execution will be key to its long-term success. Not investment advice.
